Yahoo
NYSE - Nasdaq Real Time Price USD

Boston Scientific Corporation (BSX)

42.26 -0.17 (-0.40%)
As of 10:07:47 AM EDT. Market Open.
Trade BSX on Coinbase
BSX Q3 2026 earnings call
Replay the call for the latest insights.
Chart Range Bar
Loading chart for BSX

What's happening with BSX?

20m ago
Powered by Yahoo Scout

Boston Scientific reported $5.14 billion in third-quarter revenueand $0.73 adjusted EPS (earnings per share), but an eight-business-day cybersecurity outage disrupted manufacturing and shipments. Management lowered 2026 guidance, expects fourth-quarter sales to decline, and sees 2027 as a trough yearbefore a potential recovery in 2028 and 2029.

Powered by Yahoo Scout
  • Previous Close 42.43
  • Open 41.81
  • Bid 42.51 x 30000
  • Ask 42.51 x 40000
  • Day's Range 41.93 - 43.03
  • 52 Week Range 39.57 - 105.65
  • Volume 4,370,481
  • Avg. Volume 19,444,335
  • Market Cap (intraday) 61.244B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 17.83
  • EPS (TTM) 2.37
  • Earnings Date Oct 28, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 57.34
  • Morningstar Rating Rating available with Stock Picks access

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

www.bostonscientific.com

59,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/29/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

BSX
55.68%
S&P 500 (^GSPC)
12.80%

1-Year Return

BSX
57.87%
S&P 500 (^GSPC)
12.06%

3-Year Return

BSX
14.66%
S&P 500 (^GSPC)
87.53%

5-Year Return

BSX
2.02%
S&P 500 (^GSPC)
67.66%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 5.14B
Earnings 582M
Profit Margin 11.33%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
1B
2B
3B
4B
5B
15.0%
20.0%
25.0%

Analyst Insights

View More

Analyst Price Targets

44.00
57.34 Average
42.26 Current
78.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/29/2026
Analyst Baird
Rating Action Maintains
Rating Outperform
Price Action Raises
Price Target 50 -> 51

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    16.62%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    21.07B

  • Net Income Avi to Common (ttm)

    3.5B

  • Diluted EPS (ttm)

    2.37

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    50.15%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: